BioPharma Resources

Investigational drug · Phase 3

ESA

Also called: Erythropoiesis-Stimulating Agent

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Anemia Due to Chronic Kidney Disease, Anemia of Chronic Kidney Disease.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

150

Any phase or sponsor naming "ESA"

First trial start

2025

Jul 24, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ESA", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Anemia Due to Chronic Kidney Disease
  • Anemia of Chronic Kidney Disease

Approved drugs for the same conditions: Anemia · Chronic kidney disease · Hematology and blood cancers · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "ESA" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5,013 on PubMed

Also in development for Anemia Due to Chronic Kidney Disease

  • AND017Phase 36 trials

    Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.